Network-principled deep generative models for designing drug combinations as graph sets

• URL: http://arxiv.org/abs/2004.07782v2
• Date: Wed, 22 Apr 2020 22:38:15 GMT
• Title: Network-principled deep generative models for designing drug combinations as graph sets
• Authors: Mostafa Karimi, Arman Hasanzadeh and Yang shen
• Abstract summary: Combination therapy has shown to improve therapeutic efficacy while reducing side effects. Facing enormous chemical space and unclear design principles for small-molecule combinations, the computational drug-combination design has not seen generative models to meet its potential to accelerate resistance-overcoming drug combination discovery. We have developed the first deep generative model for drug combination design, by jointly embedding graph-structured domain knowledge and iteratively training a reinforcement learning-based chemical graph-set designer.
• Score: 13.920460847160605
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Combination therapy has shown to improve therapeutic efficacy while reducing side effects. Importantly, it has become an indispensable strategy to overcome resistance in antibiotics, anti-microbials, and anti-cancer drugs. Facing enormous chemical space and unclear design principles for small-molecule combinations, the computational drug-combination design has not seen generative models to meet its potential to accelerate resistance-overcoming drug combination discovery. We have developed the first deep generative model for drug combination design, by jointly embedding graph-structured domain knowledge and iteratively training a reinforcement learning-based chemical graph-set designer. First, we have developed Hierarchical Variational Graph Auto-Encoders (HVGAE) trained end-to-end to jointly embed gene-gene, gene-disease, and disease-disease networks. Novel attentional pooling is introduced here for learning disease-representations from associated genes' representations. Second, targeting diseases in learned representations, we have recast the drug-combination design problem as graph-set generation and developed a deep learning-based model with novel rewards. Specifically, besides chemical validity rewards, we have introduced a novel generative adversarial award, being generalized sliced Wasserstein, for chemically diverse molecules with distributions similar to known drugs. We have also designed a network principle-based reward for drug combinations. Numerical results indicate that, compared to graph embedding methods, HVGAE learns more informative and generalizable disease representations. Case studies on four diseases show that network-principled drug combinations tend to have low toxicity. The generated drug combinations collectively cover the disease module similar to FDA-approved drug combinations and could potentially suggest novel systems-pharmacology strategies.

Related papers

• Emerging Drug Interaction Prediction Enabled by Flow-based Graph Neural Network with Biomedical Network [69.16939798838159]
  We propose EmerGNN, a graph neural network (GNN) that can effectively predict interactions for emerging drugs. EmerGNN learns pairwise representations of drugs by extracting the paths between drug pairs, propagating information from one drug to the other, and incorporating the relevant biomedical concepts on the paths. Overall, EmerGNN has higher accuracy than existing approaches in predicting interactions for emerging drugs and can identify the most relevant information on the biomedical network.
  arXiv  Detail & Related papers  (2023-11-15T06:34:00Z)
• SynerGPT: In-Context Learning for Personalized Drug Synergy Prediction and Drug Design [64.69434941796904]
  We propose a novel setting and models for in-context drug synergy learning. We are given a small "personalized dataset" of 10-20 drug synergy relationships in the context of specific cancer cell targets. Our goal is to predict additional drug synergy relationships in that context.
  arXiv  Detail & Related papers  (2023-06-19T17:03:46Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Unsupervised ensemble-based phenotyping helps enhance the discoverability of genes related to heart morphology [57.25098075813054]
  We propose a new framework for gene discovery entitled Un Phenotype Ensembles. It builds a redundant yet highly expressive representation by pooling a set of phenotypes learned in an unsupervised manner. These phenotypes are then analyzed via (GWAS), retaining only highly confident and stable associations.
  arXiv  Detail & Related papers  (2023-01-07T18:36:44Z)
• Tailoring Molecules for Protein Pockets: a Transformer-based Generative Solution for Structured-based Drug Design [133.1268990638971]
  De novo drug design based on the structure of a target protein can provide novel drug candidates. We present a generative solution named TamGent that can directly generate candidate drugs from scratch for a given target.
  arXiv  Detail & Related papers  (2022-08-30T09:32:39Z)
• Deep learning for drug repurposing: methods, databases, and applications [54.08583498324774]
  Repurposing existing drugs for new therapies is an attractive solution that accelerates drug development at reduced experimental costs. In this review, we introduce guidelines on how to utilize deep learning methodologies and tools for drug repurposing.
  arXiv  Detail & Related papers  (2022-02-08T09:42:08Z)
• DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations [0.9854322576538699]
  computational screening has become an important way to prioritize drug combinations. DeepDDS was superior to competitive methods by more than 16% predictive precision.
  arXiv  Detail & Related papers  (2021-07-06T08:25:43Z)
• Evening the Score: Targeting SARS-CoV-2 Protease Inhibition in Graph Generative Models for Therapeutic Candidates [11.853524110656991]
  We look at the therapeutic design of novel drug candidates targeting SARS-CoV-2 viral proteins. We use an autoencoder that generates molecules with similar structures to a dataset of drugs with anti-SARS activity. During generation, we explore optimization toward several design targets to balance druglikeness, synthetic accessability, and anti-SARS activity.
  arXiv  Detail & Related papers  (2021-05-07T18:39:25Z)
• Hybrid Attentional Memory Network for Computational drug repositioning [0.0]
  The cold start problem has always been a major challenge in the field of computational drug repositioning. We propose the Hybrid Attentional Memory Network (HAMN) model, a deep architecture combines two classes of CF model in a nonlinear manner. Our proposed HAMN model is superior to other comparison models according to the AUC, AUPR and HR indicators.
  arXiv  Detail & Related papers  (2020-06-12T02:12:32Z)
• Modeling Pharmacological Effects with Multi-Relation Unsupervised Graph Embedding [4.999039245939572]
  We present a method based on a multi-relation unsupervised graph embedding model that learns latent representations for drugs and diseases. Once representations for drugs and diseases are obtained we learn the likelihood of new links (that is, new indications) between drugs and diseases. Known drug indications are used for learning a model that predicts potential indications.
  arXiv  Detail & Related papers  (2020-04-30T14:51:25Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.